| Literature DB >> 34712107 |
Abstract
BACKGROUND: Recently, an outbreak of a novel human coronavirus SARS-CoV-2 has become a world health concern leading to severe respiratory tract infections in humans. Virus transmission occurs through person-to-person contact, respiratory droplets, and contaminated hands or surfaces. Accordingly, we aim at reviewing the literature on all information available about the persistence of coronaviruses, including human and animal coronaviruses, on inanimate surfaces and inactivation strategies with biocides employed for chemical and physical disinfection.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34712107 PMCID: PMC8548178 DOI: 10.1155/2021/9342748
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Figure 1Schematic diagram of the analysis process.
Inactivation of viruses by different types of physical disinfectants.
| Disinfection | Concentration | Virus | Strain isolate | Retention time | Reduction of viral infectivity (log10) | Reference |
|---|---|---|---|---|---|---|
| UVC (254 nm) | Dose of 3 J/m2 | SARS-CoV-2 | Isolate FFM-1 | 11–34 min | 1.0 | [ |
| UVC (254 nm) | Dose of 7 J/m2 | SARS-CoV-2 | Isolate FFM-1 | 11–34 min | 2.0 | [ |
| UVC (254 nm) | Dose of 28 J/m2 | SARS-CoV-2 | Isolate FFM-1 | 11–34 min | 3.0 | [ |
| UVC (254 nm) | Dose of 140 J/m2 | SARS-CoV-2 | Isolate FFM-1 | 11–34 min | 6.0 | [ |
| UVC (254 nm) | Dose of 6.9 J/m2 | SARS-CoV-2 | — | 2 h | 1.0 | [ |
| UVB (300 nm) | Dose of 1400 J/m2 | Vaccinia virus | — | 2 h | 2.0 | [ |
| UVC (254 nm) | Dose of 0.2 J/cm2 | SARS-CoV-2 | Frankfurt 1 | — | ≥3.4 | [ |
| UVC (254 nm) | Dose of 0.2 J/cm2 | CCHFV | Afg09-2990 | — | ≥2.2 | [ |
| UVC (254 nm) | Dose of 0.2 J/cm2 | NiV | Malaysia | — | ≥4.3 | [ |
| UVC (222 nm) | Dose of 0.56 mJ/cm2 | HCoV | 229E | — | 1.0 | [ |
| UVC (222 nm) | Dose of 0.39 mJ/cm2 | HCoV | OC43 | — | 1.0 | [ |
| Pulsed-xenon ultraviolet light | — | SARS-CoV-2 | USA-WA1/2020 | 2 min | >4.54 | [ |
| Visible light plus MB (plasma units) | 120 J/cm2 | MERS-CoV | EMC/2012 | — | ≥3.3 | [ |
| Visible light plus MB (plasma units) | 120 J/cm2 | EBOV | Mayinga-76 | — | ≥4.6 | [ |
| Gamma irradiation | 1 mrad | SARS-CoV-1 | Strain Tor 2 | 5 s | >4.0 | [ |
| Dry heat | 90°C | Poliovirus | Strain Sabin | 1 min | >4.6 | [ |
| Dry heat | 90°C | Adenovirus | Type 5 | 1 min | 3.9 | [ |
| Dry heat | 60°C | CCV | SP-80 strain | 1 min | 1.56 | [ |
| Dry heat | 60°C | MHV | RV-13 strain | 1 min | 2.87 | [ |
| Dry heat | 80°C | CCV | SP-80 strain | 1 min | >4.04 | [ |
| Dry heat | 80°C | MHV | RV-13 strain | 1 min | >3.88 | [ |
| Dry heat | 56°C | SARS-CoV | Isolate FFM-1 | 30 min | ≥5.01 | [ |
| Dry heat | 60°C | SARS-CoV | Isolate FFM-1 | 30 min | ≥5.01 | [ |
| Dry heat | 4°C | PEDV | Strain CV777 | 120 min | 0.0 | [ |
| Dry heat | 40°C | PEDV | Strain CV777 | 120 min | 1.0 | [ |
| Dry heat | 56°C | PEDV | Strain CV777 | 10 min | 1.0–1.7 | [ |
| Dry heat | 56°C | MERS-CoV | MERS-CoV strain Hu/France-FRA2_130569/2013 (FRA2) | 30 s | 0.1–0.9 | [ |
| Dry heat | 56°C | CCV | Strain S378 | 30 min | ≥5.01 | [ |
| Moist heat | 90°C | Poliovirus | Strain Sabin | 1 min | >5.0 | [ |
| Moist heat | 90°C | Adenovirus | Type 5 | 1 min | >4.1 | [ |
CCHFV: Crimean-Congo haemorrhagic fever virus; NiV: Nipah virus; EBOV: Ebola virus; MB: methylene blue; SARS: severe acute respiratory syndrome; MERS: Middle East respiratory syndrome; MHV: mouse hepatitis virus; CCV: canine coronavirus; HCoV: human coronavirus; TGEV: transmissible gastroenteritis virus; PEDV: porcine epidemic diarrhoea virus.
Inactivation of viruses by different types of chemical disinfectants.
| Disinfection | Concentration | Virus | Strain isolate | Contact time | Reduction of viral infectivity (log10) | Reference |
|---|---|---|---|---|---|---|
| Ethanol | 95% | SARS-CoV | Isolate FFM-1 | 30 s | ≥5.5 | [ |
| Ethanol | 80% | MERS-CoV | Strain EMC | 30 s | >4.0 | [ |
| Ethanol | 70% | Poliovirus | Strain Sabin | 1 min | 2.1 | [ |
| Ethanol | 70% | Adenovirus | Type 5 | 1 min | 2.4 | [ |
| 2-Propanol | 100% | SARS-CoV-2 | Isolate FFM-1 | 30 s | ≥3.31 | [ |
| 2-Propanol | 70% | SARS-CoV-2 | Isolate FFM-1 | 30 s | ≥3.31 | [ |
| Desderman (78% ethanol) | 78% | SARS-CoV-2 | Isolate FFM-1 | 30 s | ≥5.01 | [ |
| Sterillium (45% 2-propanol and 30% 1-propanol) | 45% and 30% | SARS-CoV-2 | Isolate FFM-1 | 30 s | ≥2.78 | [ |
| Hydrogen peroxide | Vapor of unknown concentration | TGEV | Purdue strain type 1 | 2-3 h | 4.9–5.3 | [ |
| Hydrogen peroxide | 0.5% | HCoV | Strain 229E | 1 min | >4.0 | [ |
| Hydrogen peroxide | 0.5% | Influenza A virus | PR-8 | 1 min | >4.75 | [ |
| Hydrogen peroxide | 0.5% | HCoV | Type 37 | 1 min | >4.25 | [ |
| Benzalkonium chloride | 0.04% | HCoV | Strain 229E | 1 min | <3.0 | [ |
| Didecyldimethylammonium chloride | 0.0025% | CCV | Strain S378 | 3 d | >4.0 | [ |
| Sodium hypochlorite | 2500 ppm | Poliovirus | Strain Sabin | 10 min | 4.5 | [ |
| Sodium hypochlorite | 2500 ppm | Adenovirus | Type 5 | 10 min | ND | [ |
| Sodium hypochlorite | 10 ppm | CCV | SP-80 strain | 10 min | 0.9 | [ |
| Sodium hypochlorite | 100 ppm | CCV | SP-80 strain | 10 min | 1.05 | [ |
| Sodium hypochlorite | 0.5–0.6% | Ebola virus | — | 10 min | 1.1 | [ |
| Sodium hypochlorite | 0.5% | HIV | — | 1 min | ≥7 | [ |
| Formaldehyde | 0.7% | SARS-CoV | Isolate FFM-1 | 2 min | >3.01 | [ |
| Formaldehyde | 1% | SARS-CoV | Isolate FFM-1 | 2 min | >3.01 | [ |
| Glutaraldehyde | 0.5% | SARS-CoV | Isolate FFM-1 | 2 min | >4.01 | [ |
| Glutaraldehyde | 2% | HCoV | Strain 229E | 1 min | >3.0 | [ |
| Glucoprotamin | 26% | SARS-CoV | Isolate FFM-1 | 2 min | >1.68 | [ |
| Magnesium monoperphthalate | 0.5% | SARS-CoV | Isolate FFM-1 | 30 min | >4.5 | [ |
| PVP-I surgical scrub (7.5 g/L available iodine) | 7.5 g/L | MERS-CoV | Isolate HCoV-EMC/2012 | 15 s | 4.64 | [ |
| PVP-I skin cleanser (4 g/L available iodine) | 4 g/L | MERS-CoV | Isolate HCoV-EMC/2012 | 15 s | 4.97 | [ |
| PVP-I gargle and mouthwash (1 g/L available iodine) | 1 g/L | MERS-CoV | Isolate HCoV-EMC/2012 | 15 s | 4.30 | [ |
| Povidone-iodine | 0.23% | SARS-CoV | Isolate FFM-1 | 15 s | 4.60 | [ |
| Povidone-iodine | 0.23% | MERS-CoV | Isolate HCoV-EMC/2012 | 15 s | 4.40 | [ |
| Povidone-iodine | 0.23% | Influenza virus A | H1N1 | 15 s | 5.67 | [ |
ND: not done; SARS: severe acute respiratory syndrome; MERS: Middle East respiratory syndrome; MHV: mouse hepatitis virus; CCV: canine coronavirus; HCoV: human coronavirus; TGEV: transmissible gastroenteritis virus.